Quick release bromocriptine (cycloset
TM) improves glycemic control in patients with diabetes failing metformin/sulfonylurea combination therapy.
This current study and analyses are original and different from any previously reported results from the Cycloset
According to San Diego-based Santarus, Cycloset is the only type 2 diabetes drug that has been approved since the Food and Drug Administration issued new guidelines in 2008 to limit the cardiovascular risks associated with some diabetes treatments.
Cycloset received FDA approval in 2009 but has never reached the market.
Over six months, 35 percent of Cycloset
users reached recommended average blood sugar levels, compared with 10 percent of diabetics given a dummy drug, Cincotta said.
Safety Study included more than 3,000 patients with T2DM who received either bromocriptine QR or placebo, in conjunction with their usual diabetes therapy.
15 November 2010 - US specialty biopharmaceutical company Santarus Inc (NASDAQ: SNTS) announced today the commercial launch of the Type 2 diabetes drug CYCLOSET
(bromocriptine mesylate) tablets in the USA.
M2 EQUITYBITES-September 9, 2010-Santarus Inc licenses CYCLOSET
for type 2 diabetes(C)2010 M2 COMMUNICATIONS http://www.m2.com
9 September 2010 - US-based biopharmaceutical company Santarus Inc (NASDAQ: SNTS), S2 Therapeutics Inc and VeroScience LLC today announced they have entered into a distribution and licence agreement granting Santarus exclusive rights to manufacture and commercialise CYCLOSET
tablets in USA.
, a quick-release oral formulation of bromocriptine mesylate, was recently approved by the Food and Drug Administration as a treatment for type 2 diabetes, according to the manufacturers, VeroScience and S2 Therapeutics Inc.